New Approaches to Drug Discovery

Dr. Ulrich Nielsch, Bayer Pharma AG,Wuppertal, GermanyDr. Ulrike Fuhrmann, Bayer Pharma AG, Berlin, GermanyProf. Dr. Stefan Jaroch, Bayer Pharma AG, Berlin, Germany

• Preface.-Part 1. Historical View.- Drug discovery in the past and today.Part 2. Target Discovery.- Emerging target families:intractable targets. In vivo target validation especially for biologicaltargets. HR RNAi/High Content analysis.- Part 3. Lead generation and Optimization.- Sources for leads: natural products,libraries. Screening: assays, readout, technology. Impact of structuralbiology, fragment based screening/Virtual screening. Predictive in silico toolsof compound properties. High throughput synthesis. New compound classes:Protein-Protein Interaction. Sources for biological leads/Screening ofbiologicals.- Part 4. Test systems forEfficacy and Safety.- In vitro/ Cell based assays. Pharmacodynamic. Pharmacokinetic. Safety and toxicology. Impactof biomarkers/personalized medicine. Simulating in vivo drug effects.